Studies of Merck & Co.’s anti- clotting drug vorapaxar, a product analysts said may generate $5 billion in sales, were halted for patients with a previous stroke, potentially limiting its use.
Interim study results suggest the experimental medication, which uses a novel method to prevent platelets within blood from clumping together, isn’t appropriate for people who suffered a stroke, researchers at Brigham and Women’s Hospital and the Duke Clinical Research Institute said in a statement today. The trial was stopped by an overview board, the institutes said.
via bloomberg.com
No comments:
Post a Comment